PriceTargets.com logo

Grace Therapeutics - GRCE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 450.46%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.18 As of 03/14/2025 02:42 PM ET
▼ -0.11 (-4.80%)

This chart shows the closing price for GRCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$2.29Closing price on 03/13/25:
Get New Grace Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRCE

Analyst Price Target is $12.00
▲ +450.46% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Grace Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 450.46% upside from the last price of $2.18.

This chart shows the closing price for GRCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
11/242/253/253/26$1.60$4.20$6.80$9.40$12Closing price on 03/13/25: $2.29High$12.00Average$12.00Low$12.00




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Grace Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 3/14/2020 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/13/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/14/2025

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Grace Therapeutics logo
Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.
Read More

Today's Range

Now: $2.18
Low: $2.07
High: $2.24

50 Day Range

MA: $3.35
Low: $2.29
High: $4.22

52 Week Range

Now: $2.18
Low: $2.07
High: $4.97

Volume

36,391 shs

Average Volume

90,026 shs

Market Capitalization

$22.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Grace Therapeutics?

The following sell-side analysts have issued research reports on Grace Therapeutics in the last year: HC Wainwright.
View the latest analyst ratings for GRCE.

What is the current price target for Grace Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Grace Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 424.0%. HC Wainwright has the highest price target set, predicting GRCE will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Grace Therapeutics in the next year.
View the latest price targets for GRCE.

What is the current consensus analyst rating for Grace Therapeutics?

Grace Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRCE will outperform the market and that investors should add to their positions of Grace Therapeutics.
View the latest ratings for GRCE.

What other companies compete with Grace Therapeutics?

Other companies that are similar to Grace Therapeutics include Adverum Biotechnologies, Cardiol Therapeutics, Exozymes, Invizyne Technologies and Atossa Therapeutics. Learn More about companies similar to Grace Therapeutics.

How do I contact Grace Therapeutics' investor relations team?

Grace Therapeutics' physical mailing address is 103 CARNEGIE CENTER SUITE 300, PRINCETON NJ, 08540. The company's listed phone number is 818-839-4378 and its investor relations email address is acst@crescendo-ir.com. The official website for Grace Therapeutics is www.acastipharma.com. Learn More about contacing Grace Therapeutics investor relations.